BGI Genomics
The BGI China multicenter program, which launched last week, is the first clinical research application of Natera's Signatera tumor-informed residual disease test in China for use with colorectal cancer patients.
Contact person: Mr. Tommy Ru
Position:
Mobi: 17722567742
Phone: - Fax:
SEND INQUIRY
Please fill in fully your information to send email
CATEGORY
